Last10K.com

Nuo Therapeutics, Inc. (AURX) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Nuo Therapeutics, Inc.

CIK: 1091596 Ticker: AURX
Document And Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Mar. 31, 2019
Jun. 30, 2018
Document Information [Line Items]   
Entity Registrant NameNuo Therapeutics, Inc.  
Entity Central Index Key0001091596  
Trading Symbolaurx  
Current Fiscal Year End Date--12-31  
Entity Filer CategoryNon-accelerated Filer  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Well-known Seasoned IssuerNo  
Entity Emerging Growth Companyfalse  
Entity Small Businesstrue  
Entity Common Stock, Shares Outstanding (in shares) 23,722,400 
Entity Public Float  $ 1.3
Entity Shell Companyfalse  
Document Type10-K  
Document Period End DateDec. 31, 2018  
Document Fiscal Year Focus2018  
Document Fiscal Period FocusFY  
Amendment Flagfalse  

View differences made from one year to another to evaluate Nuo Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nuo Therapeutics, Inc..

Continue

Assess how Nuo Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nuo Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parentheticals)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity (Deficit)
Note 1 - Description Of Business And Bankruptcy Proceedings
Note 1 - Description Of Business And Bankruptcy Proceedings (Details Textual)
Note 10 - Income Taxes
Note 10 - Income Taxes (Details Textual)
Note 10 - Income Taxes (Tables)
Note 10 - Income Taxes - Deferred Tax Assets And Liabilities (Details)
Note 10 - Income Taxes - Income Tax Expense (Benefit) (Details)
Note 10 - Income Taxes - Income Tax Rate Reconciliation (Details)
Note 11 - Fair Value Measurements
Note 11 - Fair Value Measurements (Details Textual)
Note 12 - Commitments And Contingencies
Note 12 - Commitments And Contingencies (Details Textual)
Note 12 - Commitments And Contingencies (Tables)
Note 12 - Commitments And Contingencies - Future Minimum Lease Payments (Details)
Note 13 - Subsequent Events
Note 13 - Subsequent Events (Details Textual)
Note 2 - Liquidity And Summary Of Significant Accounting Principles
Note 2 - Liquidity And Summary Of Significant Accounting Principles (Details Textual)
Note 2 - Liquidity And Summary Of Significant Accounting Principles (Tables)
Note 2 - Liquidity And Summary Of Significant Accounting Principles - Adoption Of Asu 2016-18 (Details)
Note 2 - Liquidity And Summary Of Significant Accounting Principles - Anti-Dilutive Securities Excluded From The Computation Of Diluted Earnings (Loss) Per Share (Details)
Note 2 - Liquidity And Summary Of Significant Accounting Principles - Earnings (Loss) Per Share (Details)
Note 2 - Liquidity And Summary Of Significant Accounting Principles - Summary Of Concentration Risk (Details)
Note 2 - Liquidity And Summary Of Significant Accounting Principles - Summary Stock Option Valuation Assumptions (Details)
Note 3 - Distribution, Licensing And Collaboration Arrangements
Note 3 - Distribution, Licensing And Collaboration Arrangements (Details Textual)
Note 4 - Receivables
Note 4 - Receivables (Details Textual)
Note 4 - Receivables (Tables)
Note 4 - Receivables - Accounts And Other Receivable, Net (Details)
Note 5 - Property And Equipment
Note 5 - Property And Equipment (Details Textual)
Note 5 - Property And Equipment (Tables)
Note 5 - Property And Equipment - Property And Equipment, Net (Details)
Note 6 - Goodwill And Other Intangible Assets
Note 6 - Goodwill And Other Intangible Assets (Details Textual)
Note 6 - Goodwill And Other Intangible Assets (Tables)
Note 6 - Goodwill And Other Intangible Assets - Changes In Goodwill (Details)
Note 6 - Goodwill And Other Intangible Assets - Intangible Assets (Details)
Note 7 - Accrued Liabilities
Note 7 - Accrued Liabilities (Tables)
Note 7 - Accrued Liabilities - Summary Of Accrued Liabilities (Details)
Note 8 - Convertible Notes And Stock Purchase Warrants
Note 8 - Convertible Notes And Stock Purchase Warrants (Details Textual)
Note 9 - Equity And Stock-Based Compensation
Note 9 - Equity And Stock-Based Compensation (Details Textual)
Note 9 - Equity And Stock-Based Compensation (Tables)
Note 9 - Equity And Stock-Based Compensation - Stock Option Activity (Details)
Note 9 - Equity And Stock-Based Compensation - Stock-Based Compensation Expense (Details)
Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Nuo Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AURX
CIK: 1091596
Form Type: 10-K Annual Report
Accession Number: 0001437749-19-007338
Submitted to the SEC: Tue Apr 16 2019 5:27:02 PM EST
Accepted by the SEC: Tue Apr 16 2019
Period: Monday, December 31, 2018
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aurx/0001437749-19-007338.htm